GB201006324D0 - Vaccine - Google Patents

Vaccine

Info

Publication number
GB201006324D0
GB201006324D0 GBGB1006324.6A GB201006324A GB201006324D0 GB 201006324 D0 GB201006324 D0 GB 201006324D0 GB 201006324 A GB201006324 A GB 201006324A GB 201006324 D0 GB201006324 D0 GB 201006324D0
Authority
GB
United Kingdom
Prior art keywords
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1006324.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority to GBGB1006324.6A priority Critical patent/GB201006324D0/en
Publication of GB201006324D0 publication Critical patent/GB201006324D0/en
Priority to PCT/EP2010/058328 priority patent/WO2011127989A1/en
Priority to CN2010102702104A priority patent/CN102218137A/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0013Therapeutic immunisation against small organic molecules, e.g. ***e, nicotine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
GBGB1006324.6A 2010-04-15 2010-04-15 Vaccine Ceased GB201006324D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB1006324.6A GB201006324D0 (en) 2010-04-15 2010-04-15 Vaccine
PCT/EP2010/058328 WO2011127989A1 (en) 2010-04-15 2010-06-14 Nicotine conjugate vaccine
CN2010102702104A CN102218137A (en) 2010-04-15 2010-06-15 Vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1006324.6A GB201006324D0 (en) 2010-04-15 2010-04-15 Vaccine

Publications (1)

Publication Number Publication Date
GB201006324D0 true GB201006324D0 (en) 2010-06-02

Family

ID=42245280

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1006324.6A Ceased GB201006324D0 (en) 2010-04-15 2010-04-15 Vaccine

Country Status (3)

Country Link
CN (1) CN102218137A (en)
GB (1) GB201006324D0 (en)
WO (1) WO2011127989A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10093947B2 (en) * 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US10004811B2 (en) * 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5876727A (en) 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
SE9801923D0 (en) 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
JP5084103B2 (en) 2002-07-18 2012-11-28 サイトス バイオテクノロジー アーゲー Hapten carrier conjugates and uses thereof
WO2009120954A2 (en) * 2008-03-27 2009-10-01 The Scripps Research Institute Nicotine immunoconjugates

Also Published As

Publication number Publication date
WO2011127989A1 (en) 2011-10-20
CN102218137A (en) 2011-10-19

Similar Documents

Publication Publication Date Title
GB201005005D0 (en) New vaccine
IL223206A0 (en) Vaccine formulations
IL217008A0 (en) Vaccine
GB201015132D0 (en) Vaccine composition
IL231043A0 (en) Vaccine
ZA201300395B (en) Influenza vaccine
GB201006165D0 (en) Vaccine
GB201119999D0 (en) Vaccine
ZA201301950B (en) Bvdv vaccine
GB201003293D0 (en) Cancer vaccine
EP2543387A4 (en) Mucosal vaccine
GB201001726D0 (en) Bunyavirus vaccine
EP2763699A4 (en) Vaccine
GB201014965D0 (en) Vaccine
GB201000522D0 (en) Vaccine
GB201013006D0 (en) Vaccine
GB201006324D0 (en) Vaccine
GB201120000D0 (en) Vaccine
IL217194A0 (en) Vaccine
ZA201302154B (en) Vaccine
GB201012283D0 (en) Vaccine
GB201007588D0 (en) Vaccine
GB201007589D0 (en) Vaccine
GB201008786D0 (en) Vaccines
GB201008795D0 (en) Vaccines

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)